UNSPSC 51334419: Zoloperone

This classification denotes an anxiolytic with the molecular formula C22H24FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3YU9TET43B, chemically known as 2(3h)-oxazolone, 4-(4-fluorophenyl)-5-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)- but generally known as zoloperone, which bears US NIH Compound Identifier 68696. European Medicines Agency schedules Zoloperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00182MIG.

UNSPSC 51334419 Zoloperone is a Commodity code that state and local governments use to procure pharmaceutical products, though recent solicitations tagged under this code show substantial scope variance — from naloxone and drug deactivation systems to generic multi-source pharmaceuticals and over-the-counter products to direct-to-manufacturer prescription fulfillment models. The buying pattern reflects state health agencies, county health departments, and cooperative purchasing alliances sourcing pharmaceutical inventory to support community health programs, pharmacy benefit management, and emergency response capabilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and regional cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration). The Texas HHS Commission's activity suggests state-level consolidation of pharmacy procurement strategy, while MMCAP's multistate RFP indicates growing reliance on cooperative purchasing to aggregate volumes and standardize terms across jurisdictions.

Recent activity concentrates in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford; proposals were due July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs serving self-insured state employees and health plans, functioning as exploratory market intelligence before formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. MMCAP's RFP weighted price competitiveness at 75 percent and required vendors to maintain $5 million commercial general liability and $2 million network security and professional liability insurance.